2021 THIRD QUARTERLY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUXI APPTEC CO., LTD.*

無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2359)

2021 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of WuXi AppTec Co., Ltd.* (無錫藥明康德新 藥開發股份有限公司) (the "Company", together with its subsidiaries, collectively the

"Group") for financial year 2021 (the "2021 Third Quarterly Report"). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises or the International Financial Reporting Standards issued by the International Accounting Standards Board (the "IFRSs") (as applicable) and has not been audited.

By order of the Board

WuXi AppTec Co., Ltd.*

Dr. Ge Li

Chairman

Hong Kong, October 29, 2021

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

*  For identification purpose only

- 1 -

1. Important Notice

1. The Board, the Supervisory Committee and the Directors, the supervisors and the senior management of the Company warrant the truthfulness, accuracy and completeness of the contents of the 2021 Third Quarterly Report and that there are no false information, misleading statements or material omissions in the 2021 Third Quarterly Report, and shall assume several and joint legal responsibilities.
2. Ge Li, the person in charge of the Company, Ellis Bih-Hsin Chu, the chief financial officer and Jin Sun, the director of the accounting department (person in charge of accounting) warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2021 Third Quarterly Report.
3. The 2021 Third Quarterly Report of the Company has not been audited.
4. Definitions
   Definitions of frequently-used terms

"A Share(s)"	domestic shares of the Company, with a nominal value
	of RMB1.00 each, which are listed for trading on the
	Shanghai Stock Exchange and traded in RMB
"Board"	the board of directors of the Company
"CDMO"	Contract Development and Manufacturing Organization
	that provides customized development services of related
	products in addition to process development, formulation
	development, clinical trial drugs, manufacturing of
	chemically or biologically synthesized drug substances,
	manufacturing of intermediates, manufacturing of
	preparations (such as powder and injection), packaging
	and other services which are necessary for product
	manufacturing

- 2 -

"China" or "PRC"	the People's Republic of China, which for the purpose
	of this quarterly report excludes the Hong Kong Special
	Administrative Region of the PRC, the Macao Special
	Administrative Region of the PRC and Taiwan
"clinical research"	part of medical research and health research, the
	purpose of which is to establish basic theories about
	human disease mechanisms, disease prevention and
	health promotion. Clinical research involves the study
	of doctor-patient interaction and diagnostic clinical
	information, data or patient group information
"clinical trial(s)"	systematical investigation of drugs conducted on human
	subjects (patients or healthy volunteers) to prove or
	reveal the function, adverse reactions and/or absorption,
	distribution, metabolism and excretion of the drug
	being investigated. The purpose of a clinical trial is to
	determine the therapeutic efficacy and safety of the drug
"CRDMO"	Contract Research Development and Manufacturing
	Organization
"CRO"	Contract Research Organization, an academic or
	commercial scientific organization which provides
	professional services for drug research of pharmaceutical
	enterprises and research and development organizations
	on a contract basis
"CTDMO"	Contract Testing Development and Manufacturing
	Organization
"DEL"	DNA-encoded library
"Director(s)"	the director(s) of the Company
"end of the Reporting	September 30, 2021
Period"
"H Share(s)"	overseas listed foreign shares in the share capital of the
	Company with nominal value of RMB1.00 each, which
	are listed on the Stock Exchange

- 3 -

"IFRSs"	International Financial Reporting Standards issued by
	the International Accounting Standards Board
"IND filing"	filing for clinical trial of investigational new drug (IND),
	which is necessary before commencement of clinical
	trial
"precision medicine"	a new medical concept and medical model developed
	with the rapid advancement of genome sequencing
	technology and the cross-application of bioinformatics
	and big data science based on personalized medicine.
	Its essence is to analyze, identify, verify and apply
	biomarkers for large sample populations and specific
	disease types through omics technologies such as
	genomics and proteomics as well as cutting-edge medical
	technologies so as to accurately identify the cause of
	the disease and the target of treatment. It also accurately
	classifies different states and processes of a disease, and
	ultimately achieve the goal of personalized and precise
	treatment for the disease and specific patients, and
	improve the effectiveness of disease diagnosis, treatment
	and prevention
"PROTAC"	proteolysis targeting chimera
"Reporting Period"	the period from July 1, 2021 to September 30, 2021
"RMB" or "RMB million"	Renminbi yuan or million yuan
"Share(s)"	ordinary shares in the capital of the Company with a
	nominal value of RMB1.00 each, comprising A Shares
	and H Shares
"SMO"	Site Management Organization for clinical trials
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Supervisory Committee"	the supervisory committee of the Company
"U.S."	the United States of America, its territories, its
	possession and all areas subject to its jurisdiction
"WIND"	WuXi IND service platform

- 4 -

1. Company Profile
   The Company is a leading global pharmaceutical research and development services platform. Headquartered in Shanghai, China, the Company provides comprehensive and integrated platform services of discovery, development and manufacturing of small molecule drugs for over 5,640 customers (active customers) through 30 operation sites and branch offices across the globe, including in China, the U.S. and Europe. It provides global pharmaceutical companies with discovery, manufacturing and supporting services of new drugs through a platform covering the entire industry chain, and also offers certain testing services for medical devices as well as research, development and manufacturing services of precision medicine. As at the end of the Reporting Period, the Company had 33,305 employees, including 10,643 employees with a master's or higher degree and 1,184 employees with a Ph.D. or equivalent degree. A breakdown of our employees by function and by geography is set out below:

	China
	(including
Position	Hong Kong)		U.S.		Europe		Total
Research and development	26,630	931	139	27,700
Manufacturing	2,647	219	52	2,918
Sales	34	74	27	135
Management and
administration	2,020	442	90	2,552
Total	31,331	1,666	308	33,305

- 5 -